Activation of peroxisome proliferator-activated receptor-α in mice induces expression of the hepatic low-density lipoprotein receptor

British Journal of Pharmacology

Volumn 155, Issue 4, 2008, Pages 596-605

  Huang, Z ^a   Zhou, X ^a   Nicholson, A C ^a   Gotto Jr , A M ^a   Hajjar, D P ^a   Han, J ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NANKAI UNIVERSITY   (China)

Author keywords

Akt; Fenofibrate; LDLR; PPAR ; SREBP2

Indexed keywords

2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; 2 CHLORO 5 NITROBENZANILIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; FENOFIBRATE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; HEPATOMA CELL; LIPID DIET; LIPOPROTEIN METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RECEPTOR BINDING;

ANIMALS; ANTILIPEMIC AGENTS; CELL LINE; CHOLESTEROL; CHOLESTEROL, LDL; GENE EXPRESSION REGULATION; HEPATOCYTES; HUMANS; LIVER; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; PPAR ALPHA; PROCETOFEN; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, LDL; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRANSCRIPTION, GENETIC;

EID: 53849106812     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.331     Document Type: Article

References (50)

1. Adams CM, Goldstein JL, Brown MS (2003). Cholesterol-induced conformational change in SCAP enhanced by Insig proteins and mimicked by cationic amphiphiles. Proc Natl Acad Sci USA 100: 10647-10652.
2. Anderson SP, Dunn C, Laughter A, Yoon L, Swanson C, Stulnig TM et al. (2004). Overlapping transcriptional programs regulated by the nuclear receptors peroxisome proliferator-activated receptor α, retinoid X receptor, and liver X receptor in mouse liver. Mol Pharmacol 66: 1440-1452.
3. Arca M, Montali A, Pigna G, Antonini R, Antonini TM, Luigi P et al. (2007). Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia. Metabolism 56: 1534-1541.
4. Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG (2002). Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 25: 1198-1202.
5. Backes JM, Gibson CA, Ruisinger JF, Moriarty PM (2007). Fibrates: what have we learned in the past 40 years? Pharmacotherapy 27: 412-424.
6. Bays H, Stein EA (2003). Pharmacotherapy for dyslipidaemia - current therapies and future agents. Expert Opin Pharmacother 4: 1901-1938.
7. Berthou L, Duverger N, Emmanuel F, Langouet S, Auwerx J, Guillouzo A et al. (1996). Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest 97: 2408-2416.
8. Borradaile NM, De Dreu LE, Huff MW (2003). Inhibition of net HepG2 cell apolipoprotein B secretion by the citrus flavonoid naringenin involves activation of phosphatidylinositol 3-kinase, independent of insulin receptor substrate-1 phosphorylation. Diabetes 52: 2554-2561.
9. Brown MS, Goldstein JL (1997). The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89: 331-340.
10. Brown PJ, Stuart LW, Hurley KP, Lewis MC, Winegar DA, Wilson JG et al. (2001). Identification of a subtype selective human PPARα agonist through parallel-array synthesis. Bioorg Med Chem Lett 11: 1225-1227.
11. Chatley P, Badyal DK, Calton R, Khosla PP (2007). Combination therapy of low-dose atorvastatin and fenofibrate in mixed hyperlipidemia. Methods Find Exp Clin Pharmacol 29: 217-221.
12. Davidson MH, Bays HE, Stein E, Maki KC, Shalwitz RA, Doyle R (2006). Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. Clin Cardiol 29: 268-273.
13. Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE (2004). Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clin Ther 26: 1599-1607.
14. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK et al. (2005). Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366: 1279-1289.
15. Du X, Kristiana I, Wong J, Brown AJ (2006). Involvement of Akt in ER-to-Golgi transport of SCAP/SREBP: a link between a key cell proliferative pathway and membrane synthesis. Mol Biol Cell 17: 2735-2745.
16. Duez H, Chao YS, Heranandez M, Torpier G, Poulain P, Mundt S et al. (2002). Reduction of atherosclerosis by the peroxisome proliferator-activated receptor a agonist fenofibrate in mice. J Biol Chem 277: 48051-48057.
17. Frost RJ, Otto C, Geiss HC, Schwandt P, Parhofer KG (2001). Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol 87: 44-48.
18. Gilde AJ, Fruchart JC, Staels B (2006). Peroxisome proliferator-activated receptors at the crossroads of obesity, diabetes, and cardiovascular disease. J Am Coll Cardiol 48: A24-A32.
19. Goldstein JL, Bose-Boyd RA, Brown MS (2006). Protein sensors for membrane sterols. Cell 124: 35-46.
20. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J (2005). Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 95: 462-468.
21. Han J, Parsons M, Zhou X, Nicholson AC, Gotto Jr AM, Hajjar DP (2004). Functional interplay between the macrophage scavenger receptor class B type I and pitavastatin (NK-104). Circulation 110: 3472-3479.
22. Hennuyer N, Tailleux A, Toppier G, Mezdour H, Fruchart JC, Staels B et al. (2005). PPARα, but not PPARγ, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol 25: 1897-1902.
23. Iovine C, Lilli S, Gentile A, Patti L, Di ML, Cipriano P et al. (2006). Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia. Eur J Clin Invest 36: 560-565.
24. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR et al. (2005). Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366: 1849-1861.
25. Kourimate S, Le May C, Langhi C, Jarnoux AL, Ouguerram K, Zaïr Y et al. (2008). Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/Kexin type 9. J Biol Chem 283: 9666-9673.
26. Le Jossic-Corcos C, Duclos S, Ramirez LC, Zaghini I, Chevillard G, Marti P et al. (2004). Effects of peroxisome proliferator-activated receptor α activation on pathways contributing to cholesterol homeostasis in rat hepatocytes. Biochim Biophys Acta 1683: 49-58.
27. Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG et al. (2002). Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41: 6640-6650.
28. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK (2000). Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106: 523-531.
29. Malik J, Melenovsky V, Wichterle D, Haas T, Simek J, Ceska R et al. (2001). Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial - FAT). Cardiovasc Res 52: 290-298.
30. Melenovsky V, Malik J, Wichterle D, Simek J, Pisarikova A, Skrha J et al. (2002). Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am Heart J 144: E6.
31. Motojima K (2000). Differential effects of PPARα activators on induction of ectopic expression of tissue-specific fatty acid binding protein genes in the mouse liver. Int J Biochem Cell Biol 32: 1085-1092.
32. Muhlestein JB, May HT, Jensen JR, Horne BD, Lanman RB, Lavasani F et al. (2006). The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol 48: 396-401.
33. Muoio DM, Maclean PS, Lang DB, Li S, Houmard JA, Way JM et al. (2002). Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) α knock-out mice. Evidence for compensatory regulation by PPARd. J Biol Chem 277: 26089-26097.
34. Nohturfft A, Bose-Boyd RA, Scheek S, Goldstein JL, Brown MS (1999). Sterols regulate cycling of SREBP cleavage-activating protein (SCAP) between endoplasmic reticulum and Golgi. Proc Natl Acad Sci USA 96: 11235-11240.
35. Porstmann T, Griffith B, Chung YL, Delpuech O, Griffith JR, Downward J et al. (2005). PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 24: 6465-6481.
36. Radhakrishnan A, Sun LP, Kwon HJ, Brown MS, Goldstein JL (2004). Direct binding of cholesterol to the purified membrane region of SCAP: mechanism for a sterol-sensing domain. Mol Cell 15: 259-268.
37. Saklamaz A, Comlekci A, Temiz A, Caliskan S, Ceylan C, Alacacioglu A et al. (2005). The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia. Metabolism 54: 677-681.
38. Sebestjen M, Zegura B, Keber I (2002). Both cerivastatin and fenofibrate improve arterial vasoreactivity in patients with combined hyperlipidaemia. J Intern Med 251: 77-85.
39. Shimano H (2001). Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes. Prog Lipid Res 40: 439-452.
40. Song G, Ouyang G, Bao S (2005). The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9: 59-71.
41. Staels B, Van TA, Andreu T, Auwerx J (1992). Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. Arterioscler Thromb 12: 286-294.
42. Sun L, Nicholson AC, Hajjar DP, Gotto Jr AM, Han J (2003). Adipogenic differentiating agents regulate expression of fatty acid binding protein and CD36 in the J744 macrophage cell line. J Lipid Res 44: 1877-1886.
43. Vega GL, Ma PT, Cater NB, Filipchuk N, Meguro S, Garcia-Garcia AB et al. (2003). Effects of adding fenofibrate (200 mg/day) to simvastatin (10mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 91: 956-960.
44. Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart JC, Staels B et al. (1995). Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 96: 741-750.
45. Wang TD, Chen WJ, Lin JW, Cheng CC, Chen MF, Lee YT (2003). Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 170: 315-323.
46. Wierzbicki AS (2006). FIELDS of dreams, fields of tears: a perspective on the fibrate trials. Int J Clin Pract 60: 442-449.
47. Winkler K, Weltzien P, Friedrich I, Schmitz H, Nickell HH, Hauck P et al. (2004). Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL. Exp Clin Endocrinol Diabetes 112: 241-247.
48. Wu JC, Merlino G, Fausto N (1994). Establishment and characterization of differentiated, nontransformed hepatocyte cell lines derived from mice transgenic for transforming growth factor alpha. Proc Natl Acad Sci USA 91: 674-678.
49. Yang T, Espenshade PJ, Wright ME, Yabe D, Gong Y, Aebersold R et al. (2002). Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. Cell 110: 489-500.
50. Zhou RH, Yao M, Lee TS, Zhu Y, Martins-Green M, Shyy JY (2004). Vascular endothelial growth factor activation of sterol regulatory element binding protein: a potential role in angiogenesis. Circ Res 95: 471-478.